Levosimendan Ameliorates Cardiopulmonary Function but Not Inflammatory Response in a Dual Model of Experimental ARDS.
ARDS
animal model
intensive medicine
levosimendan
milrinone
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
04
04
2022
revised:
26
04
2022
accepted:
28
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
The calcium sensitiser levosimendan, which is used as an inodilator to treat decompensated heart failure, may also exhibit anti-inflammatory properties. We examined whether treatment with levosimendan improves cardiopulmonary function and is substantially beneficial to the inflammatory response in acute respiratory response syndrome (ARDS). Levosimendan was administered intravenously in a new experimental porcine model of ARDS. For comparison, we used milrinone, another well-known inotropic agent. Our results demonstrated that levosimendan intravenously improved hemodynamics and lung function in a porcine ARDS model. Significant beneficial alterations in the inflammatory response and lung injury were not detected.
Identifiants
pubmed: 35625767
pii: biomedicines10051031
doi: 10.3390/biomedicines10051031
pmc: PMC9138326
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
Biomed Pharmacother. 2020 May;125:109943
pubmed: 32106380
Int J Oncol. 2016 May;48(5):2144-54
pubmed: 26984380
BMC Pulm Med. 2019 Jan 9;19(1):9
pubmed: 30626363
J Vis Exp. 2020 May 29;(159):
pubmed: 32538907
Am J Physiol Renal Physiol. 2006 Jun;290(6):F1453-62
pubmed: 16418300
Cardiovasc Drugs Ther. 2018 Dec;32(6):617-624
pubmed: 30402660
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
BMC Anesthesiol. 2014 May 26;14:42
pubmed: 24904234
Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L1-5
pubmed: 19411309
Curr Opin Crit Care. 2016 Feb;22(1):38-44
pubmed: 26627538
Chest. 2006 Dec;130(6):1906-14
pubmed: 17167015
Expert Rev Respir Med. 2015 Feb;9(1):55-72
pubmed: 25541289
Intensive Care Med. 2009 Aug;35(8):1412-9
pubmed: 19367398
Am J Respir Crit Care Med. 2005 Jun 1;171(11):1260-6
pubmed: 15750045
Crit Care Med. 2008 Jun;36(6):1979-81
pubmed: 18520665
J Cardiovasc Pharmacol. 2006 Oct;48(4):148-52
pubmed: 17086092
Autoimmun Rev. 2020 Jul;19(7):102562
pubmed: 32376400
Med Princ Pract. 2012;21(1):30-5
pubmed: 22024477
Tohoku J Exp Med. 2010 Oct;222(2):105-12
pubmed: 20877166
Curr Opin Crit Care. 2011 Feb;17(1):30-5
pubmed: 21157319
Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000
pubmed: 21508345
Crit Care Med. 2014 Jul;42(7):1610-8
pubmed: 24732240
Br J Pharmacol. 2001 May;133(2):237-42
pubmed: 11350859
Chest. 1995 Apr;107(4):1062-73
pubmed: 7705118
Am J Cardiol. 1997 Jun 15;79(12):1698-701
pubmed: 9202370
Chest. 1997 May;111(5):1306-21
pubmed: 9149588
Anesth Analg. 2005 Jul;101(1):206-12, table of contents
pubmed: 15976233
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Annu Rev Biochem. 2000;69:145-82
pubmed: 10966456
Mol Cell Biol. 2004 Jan;24(1):36-45
pubmed: 14673141
Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep;391(9):1021-1032
pubmed: 29922941
Thromb Haemost. 2015 Feb;113(2):350-62
pubmed: 25273157
J Crit Care. 2015 Feb;30(1):78-84
pubmed: 25128441
Respir Physiol Neurobiol. 2008 Aug 31;162(3):210-5
pubmed: 18674642
Eur Arch Otorhinolaryngol. 2019 Jul;276(7):1921-1931
pubmed: 30955065
Am J Respir Crit Care Med. 2006 May 1;173(9):1008-15
pubmed: 16456142
Cardiovasc Res. 2004 Nov 1;64(2):289-97
pubmed: 15485688
Int J Mol Sci. 2016 Dec 29;18(1):
pubmed: 28036088
J Cardiothorac Vasc Anesth. 2021 Aug;35(8):2483-2495
pubmed: 33583718
Respir Res. 2014 Sep 06;15:101
pubmed: 25189285
Br J Clin Pharmacol. 2004 Apr;57(4):412-5
pubmed: 15025738
Vascul Pharmacol. 2017 Mar;90:44-50
pubmed: 28192257
Crit Care Med. 2008 Jun;36(6):1873-9
pubmed: 18496375
Exp Cell Res. 2015 Feb 1;331(1):223-231
pubmed: 25239226
J Infect Dis. 2009 Sep 1;200(5):765-73
pubmed: 19627249